The side effects of ACEIs and ARBs may be resulting in less frequent use in a population that could benefit from these medications. A new study found that continuous ACEI/ARB use prior to dialysis ...

In patients with type 2 diabetes (T2D), the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is associated with lower rates of hyperkalemia and sustained use of guideline-recommended renin ...

Antihypertensive regimens that include a mineralocorticoid receptor antagonist carry the highest risk for hyperkalemia. Among the drug combinations that may increase serum potassium in patients with ...

The risk for hyperkalemia was highest with use of steroidal MRAs in combination with other RAASi. In patients with diabetic kidney disease, use of 2 classes of renin-angiotensin-aldosterone system ...

At one time, dual RAAS blockade was expected to provide more-complete inhibition of RAAS among patients with DKD. Results of large clinical trials dashed these hopes, finding increased risk of AKI and ...

Please provide your email address to receive an email when new articles are posted on . Overall, 38 patients had hyperkalemia before dialysis, researchers found. A daily intake of greater than 15.33 g ...

The symptoms of hyperkalemia begin with muscle weakness. As serum potassium levels rise, symptoms progress to more significant muscle twitching, weakness, nausea, and cramping. [69] Cardiac conduction ...